

The health impact of long COVID during the 2021-2022 Omicron wave in Australia: a quantitative burden of disease study

Authors

Samantha Howe, research assistant, University of Melbourne*,
slhowe@student.unimelb.edu.au #

Joshua Szanyi, doctor, University of Melbourne*, joshua.szanyi@unimelb.edu.au

Tony Blakely, Professor, University of Melbourne*, antony.blakely@unimelb.edu.au

*Population Interventions Unit, Centre for Epidemiology and Biostatistics,
Melbourne School of Population and Global Health, University of Melbourne, 207
Bouverie Street, Carlton, VIC, 3053

#Corresponding author

Funding: no funding

Sponsors: no sponsors

Ethical approval: This study did not require ethical approval.

Patient and public involvement: This study included no patient/public involvement.

Trial registration: N/A

Abstract

Objectives

To quantify the morbidity (years lived with disability; YLDs) of long COVID in Australia during the 2021-2022 Omicron BA.1/BA.2 wave.

To compare long COVID YLDs with: acute SARS-CoV-2 infection YLDs; years of life lost (YLLs) from SARS-CoV-2; and health loss from other diseases.

Design

Burden of disease study using inputs from previously published case-control, cross-sectional, or cohort studies.

Setting

Australia

Participants

People with symptomatic SARS-CoV-2 infection from 10/12/21 to 09/04/22.

Main outcomes measured

YLDs from long COVID per SARS-CoV-2 infection were estimated as the product of the prevalence, duration, and severity of each long COVID symptom.

YLDs from acute-SARS-CoV-2 infection and YLLs from deaths were also estimated.

The sum of the above three components was total COVID-19 disability-adjusted life years (DALYs).

Results

5,200 (95% uncertainty interval [UI] 2,100-8,300) YLDs were attributable to long COVID, 1,800 (95% UI 1,100-2,600) to acute-SARS-CoV-2 infection, meaning long COVID caused 74% of the overall YLDs from SARS-CoV-2 infections in the BA.1/BA.2 wave.

Total DALYs attributable to SARS-CoV-2 were 50,900 (95% UI 21,000-80,800), 2.4% of expected DALYs for all diseases in the same period.

Conclusion

Improved data on long COVID will improve the accuracy of morbidity estimates. In parallel, as data accumulates on SARS-CoV-2 infection sequelae (e.g., increased cardiovascular disease rates), total health loss is likely to be higher than estimated in this study.

Nevertheless, this study demonstrates that long COVID requires consideration in pandemic policy planning given it is responsible for the majority of direct SARS-CoV-2 morbidity, including during an Omicron wave in a highly vaccinated population.

Introduction

A post-acute phase of SARS-CoV-2 infection, commonly termed long COVID, occurs among some individuals following acute infection. Long COVID describes the persistence and/or emergence of a heterogeneous group of symptoms at least 12 weeks after acute infection.¹ There is no current consensus on the symptom profile that specifically characterises long COVID, with a wide range of symptoms being reported (Table 1).² While some studies report symptom clustering within individuals, the frequency and significance of this remains unclear and individuals most commonly report experiencing one or two symptoms.^{3,4} The aetiology of long COVID is proposed to be related to continued immune activation and persistence of the virus in the various organ systems infected during the acute period.⁵ Numerous risk factors have been identified, including a propensity towards an autoimmune response, female sex, co-morbidities such as Type 2 Diabetes Mellitus, and a more severe acute infection.^{4,6} Importantly, COVID-19 vaccination has been found to reduce the risk of long COVID.^{7,8}

Given ongoing high rates of SARS-CoV-2 transmission globally, it is important to quantify the full health impact of SARS-CoV-2 infection, including its longer-term consequences. Recent burden of disease studies have quantified long COVID by treating it as a single outcome, utilising the Global Burden of Disease (GBD) study health state of ‘post-acute consequences’ from other respiratory illnesses, or chronic fatigue syndrome, to approximate long COVID severity.⁹⁻¹¹ While these health states have some overlap with documented long COVID symptoms, they do not acknowledge the full breadth of symptoms linked to long COVID, or the heterogeneity of symptoms reported between individuals.^{2,9}

A lack of high-quality evidence regarding the prevalence and duration of symptoms hampers quantification of the long COVID burden. Many studies of long COVID lack an appropriate control group or are subject to other methodological issues. Of particular concern is selection bias from self-selection into studies by those experiencing ongoing symptoms and loss-to-follow up by those no longer symptomatic. These biases likely inflate estimates of long COVID occurrence.

Conversely, studies with insufficient follow-up time may not capture the full burden of long COVID symptoms, which are often relapsing and remitting in nature.² In addition to these design issues, the majority of published long COVID research has been conducted in cohorts of unvaccinated, pre-Omicron variant infected cases. To accurately quantify the impact of long COVID in highly vaccinated populations during Omicron waves, differences in the risk of long COVID by vaccination and variant need incorporating.

This paper addressed the following research questions: firstly, what is the extent of the morbidity attributable to long COVID resulting from Omicron variant SARS-CoV-2 infections, quantified ‘bottom-up’ from occurrence rates of each symptom and its severity and duration? Secondly, what proportion of total Disability-Adjusted Life Years (DALYs) accumulated during the 2021-2022 Omicron wave in Australia were due to long COVID, and how does this health loss compare to other major causes of health loss in Australia?

Methods

Morbidity calculations

Long COVID morbidity was calculated as that expected per symptomatic SARS-CoV-2 infected person:

Expected Long COVID morbidity per symptomatic survivor

$$\begin{aligned} &= \sum_i (Prevalence_{i \text{ only}} \times Duration_i \times Severity_i) \\ &+ \sum_i \sum_{j=i+1} (Prevalence_i \times Prevalence_j \times Min [Duration_{i \text{ or } j}] \\ &\times Severity_{i \text{ and } j}) \end{aligned}$$

where i and j indexes each possible symptom, and $Prevalence_{i \text{ only}}$ is the prevalence of symptom i minus the sum of the joint occurrence of symptom i with each other symptom (assuming symptom occurrence is independent). The prevalence of each symptom was calculated as a risk difference in symptom frequency between SARS-

CoV-2 survivors and SARS-CoV-2-negative controls, extracted from previous research (Appendix 1).^{3,12-14} The severity of each symptom was quantified as a disability weight (DW) taken from the GBD study¹⁵ for the matching health state, and best matches otherwise (e.g. DWs of other sensory conditions have been used as proxies for dysosmia and dysgeusia). $Severity_{i \text{ and } j}$ was calculated as¹⁶:

$$1 - (1 - DW_i) \times (1 - DW_j)$$

It was assumed that only initially symptomatic patients are at risk of long COVID¹⁷, and that calculations including all three-way (or higher) combinations of symptoms would make negligible difference.

The above ‘base case’ prevalence calculations were for unvaccinated individuals infected with a pre-Omicron variant of SARS-CoV-2, and were split into three sub-groups: adult community cases, adult hospitalised cases, and children (any acute disease severity).^{3,12-14} Long COVID symptom prevalence among previously hospitalised adults is approximately twice that among community cases.¹² Symptom prevalence is also lower among children (0-17 years) compared to adults.¹⁴ Duration of each symptom (from 1-week post-infection for mild/moderate cases, and 4-weeks post-infection for those hospitalised) was applied based on recent findings by Wulf Hansen et al., who reported a median duration of symptoms for community infections of 4 months, and 8.9 months for previously hospitalised cases.¹⁸ Exceptions to this have been applied to psychological symptoms, for which a shorter duration was used, and similarly for children (see Table 2).^{13,19}

These base-case prevalence’s were then multiplied by an odds ratio (OR) of 0.55 to approximate symptom prevalence among vaccinated cases based on findings from two recent studies that found reduced odds of symptoms following the acute infection by 49% and 41%, for those who had at least two COVID-19 vaccines compared to one/no vaccines.^{7,8} (Vaccination post-infection has been found to have a limited effect on long COVID occurrence – therefore, only vaccination prior to infection was considered.^{20,21}) Next, prevalence estimates were further multiplied by an OR of 0.25 based on an estimate of the reduction in prevalence of any symptoms at least 4-weeks

post-infection for Omicron variant compared to Delta variant infections in a vaccinated cohort in the United Kingdom.²² It was assumed that this association remains beyond 12 weeks post-infection. The exception to the latter multiplier was adults hospitalised with an Omicron infection; we assumed that once a case is severe enough to be hospitalised, there is no difference in resulting long COVID compared to pre-Omicron variants.

Uncertainty in base case (i.e. unvaccinated and pre-Omicron infected) long COVID estimates was modelled in a bottom-up manner (i.e. using the uncertainty about all inputs; detailed in Appendix 2), and equated to a standard deviation of +/- 20% of the expected value. For morbidity calculations for vaccinated and Omicron-infected populations, we used a standard deviation of +/- 30% of the expected value to reflect the additional uncertainty.

Application to the Omicron wave and health burden comparison

Long COVID years lived with disability (YLDs) were calculated as the expected long COVID morbidity per symptomatic case multiplied by the total number of symptomatic infections (treated as equivalent to notified cases) during the four months of the Omicron BA.1/BA.2 wave in Australia, defined here as December 10th 2021 to April 9th 2022.

The YLDs from acute SARS-CoV-2 infection were estimated as detailed in Appendix 3.

Years of life lost (YLLs) due to SARS-CoV-2 deaths were estimated using standard burden of disease methods²³, multiplying deaths due to COVID-19 with the average remaining life expectancy of those who died (with reference life expectancy by sex and age obtained from the 2019 GBD, retrieved from the Institute for Health Metrics and Evaluation [IHME] results tool).²⁴

YLL and YLD calculations were by strata of age, hospitalisation status and vaccination. The total DALYs from SARS-CoV-2 infection in these four months was just the sum of the above three components. Note that for the purposes of this paper,

we ‘repatriated’ the long COVID YLDs to the SARS-CoV-2 infections occurring in the four month window.

For comparison, we took the YLDs and DALYs in Australia for other diseases from GBD 2019 ²⁴, dividing by three to make them equivalent to the four-month duration of the BA.1/BA.2 wave.

Results

Morbidity estimates

Long COVID morbidity prevalence and decay over time for each symptom for unvaccinated pre-Omicron infection, are presented in Appendix 4. Table 2 shows the DW used for each symptom, and the estimated prevalence and average duration of that symptom among Omicron infected, unvaccinated cases; the prevalence among vaccinated cases is that shown multiplied by 0.55.

The total long COVID morbidity estimates for each sub-group are shown in Table 3.

Application to the Omicron wave

Some 4.87 million COVID-19 cases were notified in Australia during the first four months of the Omicron wave, with approximately 35,500 hospitalisations and 3,463 deaths (Appendix 5). An estimated 61% of notified cases were vaccinated at the time of infection (Appendix 5).

The overall morbidity (i.e. YLDs) resulting from infections in this period, including acute and long COVID is shown in Figure 1. Long COVID accounts for approximately 74% of the overall non-fatal COVID-19 health loss among notified cases during the first 4 months of the Australian Omicron wave, at 5,200 YLDs (95% uncertainty interval [UI] 2,100-8,300)

The overall DALYs resulting from COVID-19 infections in the four-month period was estimated at 50,900 (95% UI 21,000-80,800), of which long COVID contributed 10.2% (compared to the acute COVID-19 morbidity contribution of 3.6%).

The leading 25 causes of morbidity in Australia ranked by YLDs are presented in Figure 2 along with the estimated YLDs resulting from COVID-19 cases during the first four months of the Omicron wave. Total COVID-19 morbidity is ranked 24th, comparable to the non-fatal health loss resulting from chronic kidney disease.

The leading 25 causes of health loss in Australia ranked by DALYs, are presented in Figure 3 along with the estimated DALYs resulting from the first four months of the COVID-19 Omicron wave. The DALYs resulting from COVID-19 cases are estimated to be 2.4% of all expected DALY loss in the four months, and rank 10th among conditions (between Alzheimer's and other dementias, and drug use disorders). The 95% uncertainty interval indicates that the rank could in fact be as high as 3rd (between low back pain and falls) or as low as 24th (below alcohol use disorders).

Discussion

This is the first publication to quantify the overall health burden of COVID-19 throughout the Omicron wave in Australia. We found that long COVID contributed to approximately 74% of the non-fatal health loss resulting from COVID-19 infections in the first four months of this wave, with the total YLDs comparable to that caused by chronic kidney disease and ischaemic heart disease (Figure 2). Also significant is the overall COVID-19 disease burden calculated in this study, amounting to 50,900 DALYs over the initial four months of the Omicron wave, or the 10th highest cause of DALYs in a 4-month period in Australia (Figure 3).

The strengths of this study lie in the comprehensive approach applied to quantify long COVID morbidity across multiple patient sub-groups, and consideration of the impact of vaccination and the Omicron variant on long COVID incidence. This has not been undertaken in other studies to our knowledge. Our approach also allows for a more complete profile of symptoms, rather than treating long COVID as a single outcome. The health state ‘post-acute consequences’, applied by two recent Australian publications to estimate the long COVID health burden in Australia, encompasses fatigue, depression and body pain.^{10,11,15} By treating long COVID as a single entity, these studies assume that the average long COVID sufferer has all the symptoms included within this applied health state. A recent study by the Institute of Health Metrics quantified long COVID parameters across three separate symptom groups (cognitive difficulty, fatigue, and shortness of breath).¹⁸ In a supplementary analysis (Appendix 6), we calculated long COVID morbidity with the IHME’s estimates, and found comparable results, indicating our method and the IHME method are consistent.

This study has limitations. Long COVID is an area of rapidly emerging and evolving research, currently characterised by limited high-quality literature. As such, there is a high level of uncertainty in our findings (e.g., our ‘cross-walk’ of pre-Omicron unvaccinated data to Omicron (largely) vaccinated cases). The studies utilised for our prevalence estimates were included based on an assessment of bias and

methodological quality; however, prevalence may still be overestimated, due to the likely direction of bias to over-estimation in long COVID studies.

One-way sensitivity analyses conducted to determine the contribution of each morbidity parameter to overall uncertainty in long COVID morbidity, found the greatest contribution came from severity estimates (Appendix 7). This is of concern, given that the majority of DWs applied were made by estimation from other health states¹⁵, and points to the merit of research to better quantify severity of each long COVID symptom. Additionally, cognitive and psychological symptoms both contributed to a high level of uncertainty in overall estimates, despite only being a small proportion of the overall symptoms included in this analysis, also indicating a need for further research on the prevalence and severity of these symptoms (Appendix 7).

It is important to note that many people dying of COVID-19 have co-morbidities, so their true YLLs will be less than that measured using standard DALY methods, which assumes those dying of COVID-19 have the mortality rate specified in the reference life table.

Our findings highlight the need to factor in long COVID-related health loss when making policy decisions, in the context of the continuing Omicron wave. Whilst the prevalence of long COVID symptoms is less now among highly vaccinated populations with Omicron than it was for pre-Omicron variants among unvaccinated populations, long COVID still contributes substantial health loss when summed over all infections. The knowledge from this paper may therefore provide an imperative for policymakers to better address the healthcare needs of long COVID sufferers – few evidence-based management options currently exist.^{25,26} Specific areas of need may require prioritisation, for example psychological support for those previously hospitalised with COVID-19, for whom such symptoms are relatively common.¹³

Our analysis focused on long COVID symptoms occurring in the months following infection. However, SARS-CoV-2 infection has also been associated with persistent organ damage, and an increased risk of chronic conditions including Type 2 Diabetes Mellitus and cardiovascular disease, particularly among those who had a severe acute

infection.^{27,31} Longer-term research will be required in the future to determine the extent that SARS-CoV-2 infection causes these sequelae, which will lead to the total burden of SARS-CoV-2 being greater (perhaps considerably greater) than that quantified in this study.

Tables

Table 1: Commonly reported long COVID symptoms

Organ system/symptom group	Symptoms
Cardiopulmonary	Dyspnoea Cough ^a Sore throat Chest pain Palpitations ^a
Musculoskeletal	Muscle weakness Muscle/joint pain
Neurological	Concentration difficulty ('brain fog') Memory impairment Headache Impaired senses of taste/smell (dysosmia/dysgeusia) Numb/tingling limbs
Psychological	Depression Anxiety Insomnia COVID-19 related post-traumatic stress disorder ^a
Gastrointestinal	Diarrhoea ^a Changes to appetite ^a
Other/general symptoms	Fatigue Hair loss ^a Skin rashes ^a Eye soreness

^a Although these symptoms have been reported, they are not included in this analysis as they were not found to occur more frequently in COVID-19 cases compared to COVID-negative controls, in the controlled literature (see Appendix 1). Note that some symptoms included are only applied to certain strata in the analysis.

Table 2: Health states & estimated prevalence of each long COVID symptom among unvaccinated, Omicron-infected cases

Sequelae	DW (95% CI)	Health state/justification	Prevalence among Omicron cases (unvaccinated) ^a		Duration (months) ^b	
			Community	Hospitalised ^c	Community	Hospitalised ^c
Adults						
Dysosmia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia. Assumed to be equivalent to mild impairment of other senses.	2.6%	7.0%	4 months	9 months
Dysgeusia	0.01 (0.004-0.020)	Health state: hearing loss, mild & presbyopia Assumed to be equivalent to mild impairment of other senses.	2.1%	6.9%	4 months	9 months
Fatigue	0.051 (0.036-0.062) ^d	Health state: infectious disease, post-acute consequences (adjusted down for depression and pain). No reasonable estimate exists for fatigue in GBD study 2019, however reasonable estimates exist for muscle/joint pain, and depression. Therefore, DW applied in the present study for depression and muscle/joint pain were subtracted from ‘post-acute consequences’ DW (DW=0.219 [95% CI 0.148-0.308]), which is characterised by weakness/tiredness, depression and body pain.	2.0%	13.1%	4 months	9 months
Dyspnoea	0.019 (0.011-0.033)	Health state: chronic obstructive pulmonary disease (COPD) and other chronic respiratory problems, mild.	1.1%	10.3%	4 months	9 months
Chest pain	0.011 (0.005-0.021)	Health state: abdominopelvic problem, mild. Assumed to be equivalent to gastroesophageal reflux disease (GERD).	0.5%	4.1%	4 months	9 months
Muscle weakness	0.004 (0.001-0.008)	Health state: anaemia, mild. Mild anaemia characterised by feeling slightly weak/tired.	1.0%	11.3%	4 months	9 months
Dizziness	0.032 (0.021-	Health state: vertigo (adjusted to estimate ‘mild’ vertigo health state). Assumed that dizziness is mild form of vertigo – as there is no ‘mild’	0.6%	4.8%	4 months	9 months

	0.046) ^d	vertigo DW, 'vertigo' DW (DW=0.113 [95% CI: 0.074-0.158]) was multiplied by 0.29 (average ratio of mild/moderate DWs across all outcomes with mild, moderate, and severe ratings in the GBD study 2019).				
Muscle/joint pain	0.023 (0.013-0.037)	Health state: musculoskeletal problems, lower limbs, mild.	0.8%	6.3%	4 months	9 months
Headache	0.037 (0.022-0.057)	Health state: headache, tension-type.	0.8%	4.3%	4 months	9 months
Numb/tingling limbs	0.023 (0.013-0.037)	Health state: musculoskeletal problems, lower limbs, mild.	0.8%	7.0%	4 months	9 months
Concentration difficulty ^e	0.069 (0.046-0.099)	Health state: dementia, mild.	1.9%	10.9%	4 months	9 months
Memory impairment ^e	0.069 (0.046-0.099)	Health state: dementia, mild.	1.4%	14.3%	4 months	9 months
Insomnia	0.03 (0.018-0.046)	Health state: anxiety disorder, mild. Anxiety disorder is characterised by difficulty sleeping and concentrating.	1.3%	19.4%	3 months	3 months
Anxiety	0.03 (0.018-0.046)	Health state: anxiety disorder, mild.	N/A	11.8%	N/A	3 months
Depression	0.145 (0.099-0.209)	Health state: major depressive disorder, mild.	N/A	23.2%	N/A	3 months
Children^f						
Dysosmia	0.01 (0.004-	Health state: hearing loss, mild & presbyopia. Assumed to be equivalent to mild impairment of other senses.	2.0%		3 months	

	0.020)			
Headache	0.037 (0.022-0.057)	Health state: headache, tension-type.	1.3%	3 months
Eye soreness	0.011 (0.005-0.02)	Health state: presbyopia. No health states eye pain exist in GBD study 2019, therefore estimated from presbyopia (characterised by mild near vision loss).	0.5%	3 months
Sore throat	0.006 (0.002-0.012)	Health state: infectious disease, acute episode, mild. Assumed to be equivalent to mild upper respiratory infection.	0.5%	3 months
Cognitive difficulty	0.045 (0.028-0.066)	Health state: attention deficit hyperactivity disorder (ADHD). ADHD is characterised by difficulty with concentration and memory.	0.8%	3 months

^a Multiply by 0.55 (on odds scale) to obtain prevalence among vaccinated.

^b Duration applied from 1 week post-infection for mild (non-hospitalised) cases, or 4 weeks post-infection for hospitalised cases

^c Symptom prevalence among initially hospitalised COVID-19 cases does not differ between pre-Omicron and Omicron variants, as outlined in the Methods.

^d DW applied is not directly taken from a DW in the 2019 GBD, instead estimated by adjusting existing DWs.

^e Community and hospitalised sub-groups for cognitive symptoms are achieved through weighting of estimates from mild vs. severe sub-groups as measured by Caspersen et al.⁶

^f Children are not separated by severity of acute infection.

Health states applied were obtained from the 2019 GBD study.²⁰

CI= Confidence Interval; DW= Disability Weight; GBD= Global Burden of Disease.

Table 3: Long COVID morbidity loss expected for any COVID-19 case (where morbidity loss is the proportionate loss in quality of life over 1 year compared to full health)

Population group		Morbidity estimate (95% UI)	
		Unvaccinated	Vaccinated
Adults	Non-hospitalised	0.0016 (0.0007-0.0026)	0.0009 (0.0004-0.0014)
	Hospitalised	0.0442 (0.0182-0.0701)	0.0186 (0.0077-0.0296)
Children		0.0003 (0.0001-0.0004)	0.0001 (0.0001-0.0002)

Note the morbidity loss for someone actually with long COVID is much greater than shown here, as these are estimates of expected morbidity loss for any surviving COVID-19 case (where 'case' defines those who are symptomatic during the acute infection).

95% UI estimated using +/- 30% standard deviation.

UI= Uncertainty Interval

Figures




Figure 1: COVID-19 morbidity resulting directly from Omicron cases during the first 4-months of the Omicron wave, December 10th 2021-April 9th 2022. 95% uncertainty intervals are shown for long COVID YLD estimates, measured with +/- 30% standard deviation. Total morbidity (rightmost bar) is estimated at 7,000 YLDs. YLDs= Years Lived with Disability




Figure 2: Comparison of top YLD causes in Australia (GBD 2019) to YLDs from COVID-19, during the first 4 months of the Omicron wave (December 10th 2021-April 9th 2022). COVID-19 YLDs, separated as long COVID (blue) and acute COVID-19 (red) includes the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID YLD estimates, measured using +/- 30% standard deviation. YLDs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period.²⁰ COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; T2DM= Type 2 Diabetes Mellitus; YLD= Years Lived with Disability.




Figure 3: Comparison of top DALY causes in Australia (GBD 2019) to DALY from long COVID, and total COVID-19, during the first 4 months of the Omicron wave (December 10th 2021-April 9th 2022). COVID-19 DALYs, separated as YLD (purple) and YLL (red), include the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID DALYs, measured using +/- 30% standard deviation. DALYs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period.²⁰ COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; DALY= Disability-Adjusted Life Years; T2DM= Type 2 Diabetes Mellitus.

References

1. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *The Lancet Infectious Diseases*. 2022;22(4):e102-e7.
2. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019.
3. Caspersen IH, Magnus P, Trogstad L. Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort. *Eur J Epidemiol*. 2022.
4. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. *Nature Medicine*. 2021;27(4):626-31.
5. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. *Infection*. 2021;49(6):1163-86.
6. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell*. 2022;185(5):881-95.e20.
7. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2022;22(1):43-55.
8. Office for National Statistics (ONS). Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK: 26 January 2022 [Internet]. Newport, South Wales: ONS; 2022 Jan 26 [cited 2022 May 2]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidaftertwodosesofacoronaviruscovid19vaccineintheuk/26january2022>
9. Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. *J Clin Epidemiol*. 2022;142:54-9.
10. Australian Institute of Health and Welfare (AIHW). The first year of COVID-19 in Australia: direct and indirect health effects. Canberra, ACT: AIHW; 2021.
11. Angeles MR, Wann Arachchige Dona S, Nguyen HD, Le LK, Hensher M. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan. *BMC Public Health*. 2022;22(1):757.
12. Vedel Sørensen AI, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population. *medRxiv*. 2022:2022.02.27.22271328.
13. Magnúsdóttir I, Lovik A, Unnarsdóttir AB, McCartney D, Ask H, Kõiv K, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. *Lancet Public Health*. 2022.
14. Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. *J Infect*. 2022;84(2):158-70.
15. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;396(10258):1204-22.

16. van Baal PHM, Hoeymans N, Hoogenveen RT, de Wit AG, Westert GP. Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy. *Population Health Metrics*. 2006;4(1):1.
17. Strahm C, Seneghini M, Güsewell S, Egger T, Leal O, Brucher A, et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort. *Clin Infect Dis*. 2022.
18. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. *medRxiv*. 2022.
19. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study. *European Journal of Pediatrics*. 2022.
20. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ*. 2022;377:e069676.
21. Wisnivesky JP, Govindarajulu U, Bagiella E, Goswami R, Kale M, Campbell KN, et al. Association of Vaccination with the Persistence of Post-COVID Symptoms. *J Gen Intern Med*. 2022;37(7):1748-53.
22. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *The Lancet*. 2022;399(10343):2263-4.
23. Australian Institute of Health and Welfare (AIHW). Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2018. Canberra: AIHW; 2021.
24. Institute for Health Metrics and Evaluation (IHME). GBD results [Internet]. Seattle, WA: IHME; 2022 [cited 2022 Jun 2]. Available from: <https://vizhub.healthdata.org/gbd-results/>
25. Royal Australian College of General Practitioners (RACGP). Caring for patients with post-COVID-19 conditions [Internet]. East Melbourne, Vic: RACGP; 2021 [cited 2022 Apr 26]. Available from: <https://www.racgp.org.au/FSDEDEV/media/documents/RACGP/Coronavirus/Post-COVID-19-conditions.pdf>
26. Care of people with post-COVID-19: Version 4.0 [Internet]. Melbourne, VIC: National COVID-19 Clinical Evidence Taskforce; 2022 [cited 26 Apr 2022]. Available from: https://covid19evidence.net.au/wp-content/uploads/FLOWCHART-11-CARE-OF-PEOPLE-WITH-POST-COVID19-V4.0.pdf?_=220408-71456
27. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;372:n693.
28. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nature Medicine*. 2022.
29. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature*. 2022.
30. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(11):1265-73.

31. Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. *BMJ Open*. 2021;11(3):e048391.